# Tirzepatide and Cardiac Remodeling in HFpEF: A 50-Patient Echo Study | This GLP A 50-patient cohort found left ventricular mass down 12.4 g and E/e' improved by 1.45 on tirzepatide in obesity-related HFpEF, with no control group and BMI down 5.8 kg/m². Publisher: This GLP Editorial Team Canonical: https://thisglp.com/research/tirzepatide-hfpef-reverse-remodeling Updated: 2026-09-18 Published: 2026-09-16 [← Research](https://thisglp.com/research) Evidence # Tirzepatide and Cardiac Remodeling in HFpEF: A 50-Patient Echo Study Fifty patients, six months of tirzepatide, and every measured outcome moved the right way. BMI fell 5.8 kg/m² in the same period, and an echocardiogram reads a body as well as a heart. [This GLP Editorial Team](https://thisglp.com/about)September 20267 min readUpdated September 2026 Fifty patients, six months, every measure · left ventricular mass · −12.4 g · E/e' (diastolic filling) · −1.45 · symptom score (KCCQ) · +13.1 · six-minute walk · +43 m · BMI · −5.8 kg/m² · NT-proBNP, hs-CRP, hs-TnT · all down · NYHA class · 60% better, 0% worse · Nothing to compare against. Nobody got worse. **Research, not medical advice.** This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://thisglp.com/methodology) and [terms](https://thisglp.com/terms). ## Key takeaways - A prospective single-center cohort of 50 adults with obesity-related HFpEF starting tirzepatide. - Left ventricular mass fell 12.4 g and the E/e' filling ratio improved by 1.45 over about six months. - Symptom scores rose 13.1 points and six-minute walk distance by 43 meters. - BMI fell 5.8 kg/m² in the same period, which changes how a heart images. - There was no control group, and NYHA class worsened in nobody. Eight things were measured here and eight things improved. That is worth pausing on before reading any of them, because a study where nothing goes the wrong way is usually telling you about its design. ## What was found Fifty adults with preserved-ejection-fraction heart failure and obesity started tirzepatide in ordinary care and were followed a median of 5.8 months. [\[1\]](https://thisglp.com/research/tirzepatide-hfpef-reverse-remodeling#ref-1) Left ventricular mass fell by 12.4 g, 95% CI −15.4 to −9.4. The E/e’ ratio, a measure of how stiffly the heart fills, improved by 1.45. Symptom scores gained 13.1 points, walk distance 43 meters, and three blood markers — NT-proBNP, hs-CRP and hs-TnT — all fell. NYHA class improved in thirty patients and worsened in none — an outcome pattern worth setting beside [a small uncontrolled study where everything also improved](https://thisglp.com/research/do-glp1-drugs-help-hidradenitis-suppurativa). An echocardiogram reads a body as well as a heart BMI fell 5.8 kg/m² over the same six months. That is a large change in the thing an ultrasound has to see through, and both co-primary endpoints are measurements taken across it. This is the same problem as [a kidney measure calculated from muscle](https://thisglp.com/research/can-you-take-a-glp1-with-polycystic-kidney-disease) and we will not restate it here. The question to carry is whether the heart changed, the image changed, or both — and a cohort of this shape cannot separate them. ## What the symptom scores carry KCCQ is a questionnaire and NYHA class is a clinician’s judgment. Everyone in this study knew they had started a new drug, and most had watched their weight fall. Thirteen points is a real improvement if it is real. It is also exactly the size of thing expectation produces in an unblinded study, which is why [reading the placebo arm first](https://thisglp.com/research/do-glp1-drugs-help-knee-pain) matters so much wherever an outcome is something a person reports. ## What the numbers in brackets mean The paper reports standardized response means of −1.16 and −1.08. Those are large, and they are easy to mistake for effect sizes against a comparator. They are not. An SRM measures change relative to the variability of that same change inside one group. With no control arm there is no between-group effect to size, which is a different thing from a small one. ## Where it fits Randomized evidence already exists for this drug class in heart failure with preserved ejection fraction, and it is better evidence than this. What a real-world cohort adds is whether the same direction shows up outside a protocol. It did. That is genuinely useful, and it is all this design can deliver — the effect still needs separating from the weight, as [re-cutting the trial populations by frailty](https://thisglp.com/research/glp1-heart-failure-frailty) showed when everyone lost the same weight and not everyone felt better. The authors say their findings complement the randomized evidence and call for further evaluation, which is the right verb for fifty people in one center. ## Frequently asked Does tirzepatide improve heart function in HFpEF? This cohort found left ventricular mass down 12.4 g and diastolic filling improved over six months. Nobody was randomized, so the effect cannot be separated from the weight loss that happened alongside. Why does weight loss complicate an echocardiogram? Both main endpoints are measurements read through the body. BMI fell 5.8 kg/m² over the same period, which changes the image as well as the heart. What is a standardized response mean? A measure of change relative to how variable that change was within one group. It is not an effect size against a comparator, and this study had no comparator. How reliable are the symptom scores? KCCQ is self-reported and NYHA class is a clinician's judgment, both collected unblinded in people who knew they had started a new drug and had lost weight. ## Sources 1. \[1\] Karanxha J, et al. (2026). Association of tirzepatide with reverse cardiac remodeling and improved diastolic function in obesity-related HFpEF: A prospective real-world cohort study International Journal of Cardiology. [PMID 42710812](https://pubmed.ncbi.nlm.nih.gov/42710812/) ## Where to get it ### Best GLP-1 injections Every injectable seller we can verify, with the price each one publishes and an honest read of what the trials measured. [Compare providers →](https://thisglp.com/best/compounded-semaglutide) ## More in Evidence - [ 150 minutes · Weekly activity goal · 2 days · Muscle strengthening · Adapt · Symptoms and ability ### Exercise on Ozempic: Building Strength Without Ignoring Symptoms ](https://thisglp.com/research/exercise-on-ozempic) - [ STEP 1, semaglutide 2.4 mg vs placebo, % change at 68 weeks · LDL cholesterol · −2.5% vs +1.3% · Total cholesterol · −3.3% vs +0.1% · HDL cholesterol · +5.2% vs +1.4% · Triglycerides · −21.9% vs −7.3% · Wegovy label, Table 13. Adults without diabetes. Ozempic doses are lower. ### Does Ozempic Lower Cholesterol? What the Lipid Results in the Trials Show ](https://thisglp.com/research/does-ozempic-lower-cholesterol) - [ Where the insulin reduction came from, units per day · week 4 · 13.4 total · week 26 · 21.9 · the drug itself · the weight loss · The drug’s own contribution barely moved: 11.1 then 11.4. · Everything added between weeks 4 and 26 came from weight. ### Does Semaglutide Help Type 1 Diabetes? What Two Small Trials Found ](https://thisglp.com/research/semaglutide-in-type-1-diabetes)